Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 654 | 40% |
| 2020 | 11 | 518 | 43% |
| 2021 | 16 | 621 |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 80% of the cases CMS names in Missouri; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 93 | 6,170+1.6%/yr | +1.6%/yr | 9.51.1× | 28% | 8,640 in 2030+5.8%/yr |
| Spinal cord & DRG stimulation |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Ohio
| ≈ 850 |
| – |
| 2026 est. | ≈ 910 | – |
| 48% |
| 2022 | 13 | 624 | 51% |
| 2023 | 19 | 785 | 55% |
| 2024 | 16 | 810 | 57% |
| 2025 from claims | – | 850 687–998 | 58% |
| 2026 forecast | – | 910 713–1,143 | 58% |
| 2027 forecast | – | 973 721–1,286 | 59% |
| 2028 forecast | – | 1,039 736–1,435 | 60% |
| 2029 forecast | – | 1,110 755–1,592 | 60% |
| 2030 forecast | – | 1,186 777–1,760 | 61% |
In 2025, 68% hospital outpatient, 15% surgery center, 17% office.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~910 | ~600 | ~160 | ~150 |
| 2027 · ~970 | ~630 | ~180 | ~160 |
| 2028 · ~1,000 | ~670 | ~200 | ~170 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 19% (15% in 2025), hospital outpatient about 64% (68% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| 1,1110%/yr |
| 0%/yr |
| 1.5 |
| 70% |
| 1,390 in 2030+3.8%/yr |
| Illinois | 14 | 1,015+11%/yr | +11%/yr | 0.7 | 41% | 2,110 in 2030+13%/yr |
| Wisconsin | 8 | 775+8.3%/yr | +8.3%/yr | 1.3 | 50% | 1,500 in 2030+12%/yr |
| Michigan | 9 | 674−6.2%/yr | −6.2%/yr | 0.7 | 49% | 680 in 20300%/yr |
| Kansas | 14 | 652+2.5%/yr | +2.5%/yr | 1.5 | 52% | 990 in 2030+7.2%/yr |
| Minnesota | 10 | 570+1.3%/yr | +1.3%/yr | 1.1 | 65% | 1,150 in 2030+12%/yr |
| Nebraska | 7 | 421+7.4%/yr | +7.4%/yr | 1.5 | 66% | 620 in 2030+6.8%/yr |
| Iowa | 3 | 187+13%/yr | +13%/yr | 0.4 | 34% | 470 in 2030+17%/yr |
| South Dakota | 7 | 186+0.7%/yr | +0.7%/yr | 1.4 | 0% | 230 in 2030+3.3%/yr |
| 21 |
| 634−4.8%/yr |
| −4.8%/yr |
| 0.91.4× |
| 41% |
| 660 in 2030+0.5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Mml leads with 46% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 9 companies reported engagement with Missouri’s surgeons worth $85K in consulting, speaking, meals and travel tied to these products, about $5,290 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.